目的 评价口服核苷类似物富马酸丙酚替诺福韦治疗宫颈持续性高危型人乳头瘤感染患者的疗效。方法 本回顾性研究中,将同一亚型高危型人乳头瘤病毒感染超过1年患者随机分为两组,治疗组给予口服富马酸丙酚替诺福韦,25 mg,每天一次,连续3个月;对照组给予宣教说明,无特殊处理。于入组后第3个及第6个月随诊。检测患者宫颈人乳头瘤病毒感染的变化,同时观察宫颈细胞学、阴道镜Reid评分及宫颈组织病理学变化。结果 宫颈持续性高危型人乳头瘤病毒感染者共82例,分为两组:治疗组42例,对照组40例。均完成随访。在治疗结束时、治疗结束后3个月,治疗组清除人乳头瘤病毒的有效率分别为 52.38% 和 61.90%,优于对照组20.00%(P＜0.05)和30.00% (P＜0.05);治疗结束时、治疗结束后3个月,治疗组细胞学异常的缓解率分别为66.67%和77.78%,优于对照组22.22%(P＜0.05)和33.33%(P＜0.05);治疗组中Reid评分3分及其以上者例数较对照组少(2 vs 10,P＜0.05),且Reid评分较基线明显下降(P＜0.05),对照组Reid评分无显著变化(P＞0.05)。6个月时治疗组中宫颈上皮内瘤变I级者组织学缓解率优于对照组(72.72% vs 35.00%,P＜0.05)。随访期间无严重不良反应。结论 口服富马酸丙酚替诺福韦可有效清除宫颈持续性高危型人乳头瘤病毒感染,且安全、临床可行。

Objective To investigate the clinical efficacy of nucleoside analogues Tenofovir Alafenamide (TAF) therapy for cervical high-risk HPV (HR-HPV) infection. Methods In this prospective study, a total of 82 patients with persistent cervical HR-HPV infection were randomly divided into two groups. The treatment group (42 patients) administered orally TAF (25mg, once daily, 3 months). The control group (40 patients) received no treatment. All patients were followed up for 6 months. HPV testing, ThinPrep cytology test (TCT), and Reid colposcopic index (RCI) grading were performed for both groups. Results HR-HPV remission rates were 52.38% and 61.9% in the treatment group at the 3-and 6-month follow-up, respectively, whereas 20% and 30% in the control group at the 3-and 6-month follow-up visits. Conversion rates of abnormal TCT results were 66.67% and 77.78% in the treatment group at two follow-up visits. In contrast, the control group showed remission rates at 22.2% and 33.3%, respectively. There were 2 and 10 patients with grade of 3-4 or higher at the treatment group and the control group at the 6-month visit, respectively. RCI scoring was declining obviously at 6 months in the treatment group (P<0.05), whereas the control group showed no significantly difference. 16 of 22 (72.72%) patients with CINⅠin the treatment group were alleviated at 6-month visit compared to 35% in the control group(P<0.05). No serious adverse events happened during the treatment and follow up. Conclusion Tenofovir alafenamide is an effective, safe and accessible treatment for cervical HR-HPV infection.

目的 探讨宫颈病变诊断中HPV联合TCT(薄层液基细胞学)检测的预测价值。方法 本文将2019年2月—2020年2月收治的宫颈病变患者90例作为研究对象,对所有患者实施HPV检测、TCT检测及阴道镜活检,将阴道镜检查结果作为金标准,统计分析TCT检测与病理结果比较、HPV检测与病理结果比较、联合检测与病理结果比较及诊断准确率。结果 90例患者经病理检查显示宫颈正常27例、CINⅠ期27例、CINⅡ期11例、CINⅢ期14例、宫颈癌11例;TCT检测显示宫颈正常19例、ASCUS 33例、LSIL 22例、HSIL 12例、SCC 4例。经HPV检测显示阳性73例,阴性17例;联合检测显示阳性88例,阴性2例;联合检测准确率与病理结果之间差异无统计学意义,P＞0.05。结论 HPV检测联合TCT检测在宫颈病变中具有较高的预测价值,准确度较高且具有无创性,可有效降低阴道镜活检的概率或者手术探查的概率,患者医疗负担相对较轻,可将其应用于宫颈病变的大规模筛查中。

Objective To investigate the predictive value of HPV combined with TCT (thinprep cytology test) in the diagnosis of cervical lesions. Methods 90 patients with cervical lesions from February 2019 to February 2020 were selected as the research objects. HPV detection, TCT detection and colposcopy biopsy were carried out for all patients. The colposcopy results were taken as the gold standard. The comparison of TCT detection and pathological results, HPV detection and pathological results, joint detection and pathological results comparison and diagnostic accuracy were statistically analyzed. Results Pathological examination showed that 27 cases of normal cervix, 27 cases of CIN Ⅰ, 11 cases of CIN Ⅱ, 14 cases of CIN Ⅲ and 11 cases of cervical cancer; TCT showed 19 cases of normal cervix, 33 cases of ASCUS, 22 cases of LSIL, 12 cases of HSIL and 4 cases of SCC. HPV test showed that 73 cases were positive and 17 cases were negative; 88 cases were positive and 2 cases were negative by combined detection; there was no significant difference between the accuracy of combined detection and pathological results, P>0.05. Conclusion HPV detection combined with TCT detection in cervical lesions has high predictive value, high accuracy and non-invasive. It can effectively reduce the probability of colposcopy biopsy or surgical exploration. It makes patients with relatively light medical burden, may be applied to large-scale screening of cervical lesions.

目的 利用高精确的外照射治疗技术,即图像引导放射治疗/容积旋转调强放疗(IGRT/VMAT) 时,使用千伏锥形束CT (kV-CBCT)定位来获得最佳的宫颈癌治疗获益。方法 205例接受IGRT/VMAT治疗的宫颈癌患者纳入实验组。每周做一次kV-CBCT定位后,将这些图像与计划CT扫描图像匹配后记录摆位误差。总共研究了1 025个kV-CBCT图像。采取同时期常规X片定位的90例宫颈癌患者作为对照组。根据定位中的摆位误差计算计划靶区(PTV)的边界。结果 实验组前后、上下和左右方向的摆位误差分别为(1.8±1.1)mm、(2.8±2.2)mm和(1.7±1.4)mm,对照组分别为(2.8±2.1)mm、(3.9±2.2)mm和(2.7±2.4)mm,两组差异具有统计学意义(P<0.05)。实验组前后、上下和左右方向的CTV-PTV边界分别为5.27 mm、8.54 mm和5.23 mm,对照组分别为8.47 mm、11.29 mm和8.43 mm。结论 在采用高精度技术治疗宫颈癌时,每周kV-CBCT是一种令人满意的精确定位方法,有助于减少CTV-PTV边界。

Objective To obtain the best cervical cancer treatment benefit through kilovoltage cone-beam CT (kV-CBCT) positioning, by using high-precision external beam therapy technology, that is, image-guided radiation therapy/volumetric modulated arc therapy (IGRT/VMAT). Methods Two hundred and five patients with cervical cancer treated with IGRT/VMAT were included in the experimental group. After kV-CBCT positioning once a week, these images were matched with the planned CT scan images and the setup errors were recorded. A total of 1 025 kV-CBCT images were studied. Ninety patients with cervical cancer positioned by conventional X-ray during the same period were selected as the control group. The boundary of the planned target volume (PTV) was calculated based on the setup errors. Results In the experimental group, the setup errors in the anteroposterior, superoinferior and mediolateral direction were (1.8±1.1) mm, (2.8±2.2) mm, and (1.7±1.4) mm, respectively. And in the control group, the setup errors were (2.8±2.1) mm, (3.9±2.2) mm, and (2.7±2.4) mm, respectively. The differences between the two groups were statistically significant (P<0.05). In the experimental group, the CTV-PTV boundaries in the anteroposterior, superoinferior and mediolateral direction were 5.27 mm, 8.54 mm, and 5.23 mm, respectively. And in the control group, the CTV-PTV boundaries were 8.47 mm, 11.29 mm, and 8.43 mm, respectively. Conclusion When using high-precision technology to treat cervical cancer, weekly kV-CBCT is a satisfactory and accurate positioning method, which helps to reduce the CTV-PTV boundary.

目的 探讨超声引导下宫颈癌根治术的应用效果及对患者远期生存率的影响。方法 选取本院2015年1月—2017年12月共收治的70例宫颈癌患者作为研究对象,将2016年7月—2017年12月纳入的患者作为观察组,2015年1月—2016年6月纳入的患者作为对照组,各35例,给予对照组患者常规腹腔镜根治术,给予观察组患者超声引导定位下腹腔镜宫颈癌根治术联合高强度凝聚超声热凝技术治疗。对比两组患者的治疗效果、远期生存率与复发率以及术后6个月、1年、2年、3年的FACT-G评分情况。结果 两组疾病控制率对比无差异(97.14% vs 85.71%,P＞0.05);观察组的治疗总有效率为高于对照组的(85.71% vs 60.00%,P＜0.05);观察组和对照组患者1年生存率对比无差异(P＞0.05),观察组2年、3年生存率高于对照组(P＜0.05),观察组和对照组1年局部复发率对比无差异(P＞0.05),观察组的2年、3年局部复发率低于对照组(P＜0.05);观察组术后6个月、1年、2年、3年的FACT-G评分高于对照组(P＜0.05)。结论 应用超声引导定位下腹腔镜宫颈癌根治术联合高强度凝聚超声热凝技术治疗宫颈癌能够提升患者的治疗效果,减少疾病复发和提高远期生存率,提升患者的生存质量,值得临床应用推广。

Objective To investigate the application effect of ultrasound-guided radical hysterectomy for cervical cancer and its influence on the long-term survival rate of patients. Methods A total of 70 patients with cervical cancer admitted from January 2015 to December 2017 were selected as the research subjects, and the patients enrolled from July 2016 to December 2017 were selected as the observation group, patients from January 2015 to June 2016 as the control group, each with 35 cases. The control group was given conventional laparoscopic radical hysterectomy, and the observation group was given ultrasound-guided laparoscopic radical hysterectomy combined with high-intensity ultrasound coagulation technology. The treatment effect, long-term survival rate, recurrence rate and FACT-G scores 6 months, 1 year, 2 years and 3 years after operation were compared between the two groups. Results There were no significant differences in disease control rates between the two groups (97.14% vs 85.71%, P>0.05); the total effective rate of treatment in the observation group was higher than that in the control group (85.71% vs 60.00%, P<0.05). There was no significant difference in the 1-year survival rate between the observation and the control group (P>0.05). The 2-year and 3-year survival rate of the observation group were higher than that of the control group (P<0.05). There was no significant difference in comparison of 1-year local recurrence rate between the observation group and the control group (P>0.05). The 2-year and 3-year local recurrence rate of the observation group were lower than that of the control group (P<0.05). FACT-G scores in the observation group after surgery at 6 months, 1 year, 2 years, and 3 years were significantly higher than the control group (P<0.05). Conclusion The application of ultrasound-guided laparoscopic radical hysterectomy combined with high-intensity ultrasound coagulation in the treatment of cervical cancer can improve the treatment effect, reduce disease recurrence rate, increase long-term survival rate, and improve the quality of life of patients, which is worthy of clinical application and promotion.

目的 探讨在小剂量催产素基础上分别联合普贝生和COOK宫颈扩张球囊对足月妊娠引产的临床效果。方法 抽取110例足月妊娠孕妇住院资料,根据引产方式不同分为两组,各55例。A组采用小剂量催产素引产,B组在A组基础上加用COOK球囊引产,比较两组促宫颈成熟效果、母婴结局以及不良并发症情况。结果 两组孕妇引产前后Bishop 评分相比,差异显著（P<0.01）,此外,与A组相比,B组引产后Bishop 评分升高（P<0.01）。A组促宫颈成熟效果有效人数为48例,新生儿Apgar 评分为9.12±2.11,产后出血量（210.7±55.44）mL,阴道分娩人数为40例,而B组引产过程中各指标均显著改善。此外,B组未出现宫内感染和胎盘早剥,而胎儿窘迫和其他并发症降低（P<0.01）。结论 催产素联合COOK球囊对足月妊娠孕妇促宫颈成熟效果显著,降低剖腹产,母婴状态良好,减少不良并发症发生。

目的 探讨产后出血(PPH)应用一次性囊式宫颈扩张器治疗的临床效果。方法 选取我院2001年1月—2016年12月收治的50例PPH产妇,按就诊先后顺序进行分组,2001年1月—2015年12月就诊的25例为对照组(予以宫腔填塞纱布治疗);2016年1月—2016年12月就诊的25例为观察组(给予一次性囊式宫颈扩张器治疗),并按照分娩方式不同分为阴道分娩组(15例),剖宫产组(10例)。记录比较观察组和对照组的治疗与预后情况;阴道分娩组与剖宫产组的治疗情况。结果 与对照组比较,观察组在操作时间、填塞物留置时间及起效时间方面,均显著更优(P<0.01);两组放置后12 h出血量、显效率相比,差异无统计学意义(P>0.05);观察组子宫切除、子宫动脉结扎及产褥感染等发生率均低于对照组,但差异均无统计学意义(P>0.05);阴道分娩组的起效时间、留置时间、T2时间段阴道总流血量、显效率及产褥感染率,较剖宫产组比较,差异均无统计学意义(P>0.05),阴道分娩组T1时间段阴道总流血量显著低于剖宫产组(P<0.01)。结论 PPH产妇应用一次性囊式宫颈扩张器治疗操作简便,更有利于缩短操作时间,改善预后,效果切实,且对于阴道分娩与剖宫产产妇的疗效相当,适用于基层医院,具有较高临床推广价值。

目的 探讨追踪护理模式对中青年保留神经宫颈癌根治术后膀胱功能恢复的影响效果。方法 按住院先后顺序将82例患者分为对照组40例、实验组42例,对照组给予常规护理,实验组实施追踪护理模式,3个月后对两组患者的尿失禁、尿潴留发生率,膀胱功能恢复情况及尿失禁严重程度进行测评。结果 实验组尿失禁、尿潴留的发生率分别为2%、4% ,膀胱功能Ⅰ级、Ⅱ级达100%,68%患者无尿失禁,与对照组比较差异均有统计学意义(P>0.05)。结论 对中青年保留神经宫颈癌根治术实施追踪护理模式,可提高患者膀胱功能锻炼的有效性,促进膀胱功能的早日恢复,改善其生活质量。

Objective To explore the effect of follow-up nursing on the recovery of bladder function in young and middle-aged patients with cervical cancer after radical operation. Methods 82 patients were divided into control group (n = 40) and experimental group (n=42). The control group was given routine nursing care, experimental group to implement the follow-up nursing model. After 3 months, the incidence of urinary incontinence and urinary retention were observed in the two groups, including bladder function recovery and severity of urinary incontinence. Results The incidence of urinary incontinence and urinary retention in the experimental group were 2% and 4%, respectively. Bladder function level I and II reached 100%. There was no urinary incontinence in 68% patients. Compared with the control group, the difference was statistically significant (P>0.05). Conclusion It may improve the effectiveness of bladder function training, promote the early recovery of bladder function and improve the quality of life of young and middle-aged patients with cervical cancer.

目的 研究鳞癌抗原(SCC-Ag)的表达对宫颈癌手术治疗后临床转归的预测价值。方法 选取我院2014年4月—2015年9月实施宫颈癌手术的患者52例,分别于手术前后分析所有患者的鳞癌抗原表达,对患者进行1年的随访,以发生癌细胞转移、复发或死亡为研究终点,比较预后良好的患者与预后差的患者鳞癌抗原的表达的不同。结果 Ia、Ib1、Ib2、IIa、IIb期宫颈癌患者术后SCC-Ag水平较手术前均显著降低(P＜0.05);纳入本次研究的患者宫颈癌术后复发或转移发生率为15.38%,转归良好的患者为84.62%,预后良好的患者术后SCC-Ag水平(0.91±0.27)ng/mL较发生复发或转移的患者(1.37±0.57)ng/ml显著较较低(P＜0.05)。结论 宫颈癌患者术后血清SCC-Ag水平与肿瘤的应答之间具有关联性,术后SCC-Ag水平高的患者复发与转移发生率显著高于SCC-Ag水平低的患者,鳞癌抗原的表达对宫颈癌手术后患者的转归情况具有预测价值,临床应予以重视。

目的 探讨妇科门诊宫颈癌高危人群采取阴道镜检查后配合宫颈细胞学检查对宫颈癌筛查价值。方法 选取2016年2月—2017年4月我院妇科门诊就诊合并宫颈癌高危患者387例为研究对象,所有患者均行阴道镜检查和宫颈细胞学检查,以最终病理检查为诊断“金标准”,探究阴道镜、宫颈细胞学检查在宫颈癌中筛查灵敏度、特异度及阳性符合率。结果 387例纳入研究宫颈癌高危患者,经病理诊断后明确诊断为宫颈癌51例,占13.18%。细胞学检查在宫颈癌中筛查灵敏度为72.55%,特异度为90.48%,阳性符合率为88.11%。阴道镜检查在宫颈癌中筛查灵敏度为50.98%,特异度为94.64%,阳性符合率为88.89%。宫颈癌筛查中,细胞学检查灵敏度高于阴道镜检查,特异度低于阴道镜检查(P＜0.05),两者检查阳性符合率比较差异无统计学意义(P＞0.05)。结论 妇科门诊宫颈癌高危患者宫颈筛查中,阴道镜筛查具有较高特异度,细胞学检查具有较高灵敏度,联合检查能提高筛查价值。

目的 研究探讨南沙区宫颈癌HPV筛查的认知程度及干预工程的效果。方法 选取2014年7月—2015年6月通过随机抽样抽取的南沙区21～60岁的妇女1000例为研究对象,通过问卷对其宫颈癌认知情况进行调查,并且根据筛查结果进行有针对性的干预措施。结果 南沙区的妇女只有35%既往有按时定期进行宫颈癌的筛查,只有13%做过HPV的筛查。筛查的900例中,HPV感染率6.78%,其中CIN1级为0.78%,CIN2级为0.44%,CIN3级为0.33%,疑浸润癌为0.11%。结论 南沙区妇女对宫颈癌HPV筛查的认知程度较低,通过对育龄妇女实施HPV筛查及干预工程,能够针对不同人群给予有针对性的干预措施,对农村育龄妇女的宫颈癌早期诊断及预防具有积极的意义。